A series of recombinant adeno-associated viral vectors (rAAVs), construction methods and uses thereof are disclosed. Each one of the rAAVs is obtained by replacing adeno-associated virus structure gene with one of the following tumor antigen genes: PSA, PSMA, CEA, CK19, Her-2/neu, LMP-1, BA46 or AFP, or mutant type of each gene, respectively. Each one of the rAAVs of the present invention can deliver its carried wild-type or mutant prostate specific antigen gene into monocyte-macrophage-dendritic cell lines to stimulate effector cells of immune system. It has been experimentally showed that CTL induced by DC, which is infected with one of the rAAVs of the present invention, can effectively inhibit the growth of malignant tumor cells or kill tumor cells in vivo in patients. The recombinant adeno-associated viral vectors of this invention and their related products can be used to prepare the medicaments for the treatment of prostatic cancer, epithelial cell malignant tumor, breast cancer, colon cancer, stomach cancer, adenocarcinoma of lung, lung cancer, oophoroma, nasopharyngeal carcinoma, cervical carcinoma, squamous carcinoma of lung, liver cancer, etc.